21-Nov-2024
Optimism over global healthcare sector rises: Jefferies
Seeking Alpha News (Thu, 21-Nov 1:45 PM ET)
Insulet's Omnipod 5 now compatible with Abbott's FreeStyle Libre 2 Plus
Seeking Alpha News (Wed, 20-Nov 10:43 AM ET)
Wells Fargo Reaffirms Their Buy Rating on Abbott Laboratories (ABT)
TipRanks (Wed, 20-Nov 4:57 AM ET)
Wells Fargo Sticks to Its Buy Rating for Abbott Laboratories (ABT)
TipRanks (Sun, 17-Nov 9:36 AM ET)
First mpox case linked to African outbreak reported in U.S.
Seeking Alpha News (Sun, 17-Nov 1:50 AM ET)
Seamless Data: Tidepool and Abbott's New Cloud-to-Cloud Integration Partnership
Business Wire (Mon, 28-Oct 8:00 AM ET)
Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure
PRNewswire (Thu, 24-Oct 9:00 AM ET)
Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range
PRNewswire (Wed, 16-Oct 7:30 AM ET)
PRNewswire (Thu, 10-Oct 9:00 AM ET)
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Abbott Laboratories trades on the NYSE stock market under the symbol ABT.
As of November 21, 2024, ABT stock price climbed to $117.26 with 4,631,207 million shares trading.
ABT has a beta of 0.15, meaning it tends to be less sensitive to market movements. ABT has a correlation of 0.01 to the broad based SPY ETF.
ABT has a market cap of $203.38 billion. This is considered a Mega Cap stock.
Last quarter Abbott Laboratories reported $11 billion in Revenue and $1.21 earnings per share. This beat revenue expectation by $85 million and exceeded earnings estimates by $.01.
In the last 3 years, ABT traded as high as $142.60 and as low as $89.67.
The top ETF exchange traded funds that ABT belongs to (by Net Assets): VTI, VOO, SPY, IVV, VTV.
ABT has underperformed the market in the last year with a return of +17.2%, while the SPY ETF gained +32.5%. In the last 3 month period, ABT fell short of the market, returning +5.8%, while SPY returned +6.2%. However, in the most recent 2 weeks ABT has outperformed the stock market by returning +1.7%, while SPY returned -0.3%.
ABT support price is $114.39 and resistance is $117.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABT shares will trade within this expected range on the day.